Aspire Biopharma (NASDAQ:ASBP) Announces Earnings Results

Aspire Biopharma (NASDAQ:ASBP) issued its quarterly earnings results on Friday. The company reported ($20.57) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.03 million for the quarter.

Aspire Biopharma Trading Down 4.4%

Shares of ASBP stock traded down $0.26 during trading hours on Friday, hitting $5.61. The company’s stock had a trading volume of 115,691 shares, compared to its average volume of 1,323,021. The company has a 50 day moving average of $20.67 and a 200 day moving average of $90.13. The stock has a market cap of $936,870.00, a PE ratio of -0.28 and a beta of 0.21. Aspire Biopharma has a 12-month low of $3.31 and a 12-month high of $1,050.36.

Analyst Ratings Changes

Several analysts have recently commented on ASBP shares. Wall Street Zen raised shares of Aspire Biopharma to a “sell” rating in a report on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Aspire Biopharma presently has an average rating of “Sell”.

Institutional Trading of Aspire Biopharma

A number of hedge funds have recently added to or reduced their stakes in ASBP. CIBC Bancorp USA Inc. purchased a new stake in Aspire Biopharma during the third quarter worth $28,000. XTX Topco Ltd lifted its stake in shares of Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after buying an additional 237,620 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Aspire Biopharma by 625.8% in the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after buying an additional 131,533 shares in the last quarter. 19.17% of the stock is owned by hedge funds and other institutional investors.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.